







FIG. 1





CI, confidence interval; d, dexamethasone; HR, hazard ratio; IRC, independent Review Committee; Isa, isatuximab; ITT, intent to treat; K, carfilzomib; m, median; NE, not estimable; NR, not reached; PFS, progression-free survival

FIG. 3



*Prior treatment at last line

CI, confidence interval; d, dexamethasone; eGFR, estimated glomerular filtration rate; IMiD, immunomodulatory drug; Isa, isatuximab; K, carfilzomib; Len, lenalidomide; MDRD, modified of diet in renal disease; PFS, progression-free survival; ISS, International Staging System

FIG. 4




FIG. 5

CI, confidence interval; d, dexamethasone; HR, hazard ratio; Isa, isatuximab; ITT, intent to treat; K, carfilzomib; NE, not estimable; NR, not reached; TNT, time to next treatment




FIG. 6

CI, confidence interval; d, dexamethasone; HR, hazard ratio; I, isatuximab; K, carfilzomib; MRD, minimal residual disease; PFS, Progression-free survival.

7/7

Subgroup		Isa-Kd No. of events/total no.	Kd No. of events/total no.	Hazard ratio (95% CI)
All patients		48/179	55/123	0.531 (0.359-0.786)
Age	<65 years	25/88	26/66	0.640 (0.370-1.109)
	≥65 years	23/91	29/57	0.429 (0.248-0.742)
Gender	Male	27/101	28/68	0.589 (0.347-1.000)
	Female	21/78	27/55	0.449 (0.253-0.797)
Race	White	34/131	36/83	0.543 (0.339-0.867)
	Other	8/34	12/28	0.511 (0.208-1.251)
Baseline ECOG PS	0 or 1	42/168	51/118	0.494 (0.328-0.744)
	>1	6/11	4/5	0.770 (0.215-2.758)
Baseline eGFR (MDRD)	≥60 ml/min/1.73 m ²	32/122	38/93	0.625 (0.391-1.001)
	<60 ml/min/1.73 m ²	10/43	10/18	0.273 (0.113-0.660)
MM type at study entry	IgG	32/126	37/85	0.517 (0.322-0.830)
	Non-IgG	16/53	18/38	0.512 (0.261-1.005)
ISS staging at study entry	I	20/89	24/71	0.592 (0.327-1.071)
	II	17/63	16/31	0.375 (0.188-0.748)
	III	11/26	14/20	0.650 (0.295-1.434)
R-ISS stage at study entry	I or II	38/155	46/105	0.463 (0.301-0.712)
	III	9/18	8/13	0.946 (0.364-2.457)
	Not classified	1/6	1/5	1.291 (0.081-20.647)
Cytogenetic abnormality*	At least one	17/42	15/31	0.724 (0.361-1.451)
	None	27/114	35/77	0.440 (0.266-0.728)
del(17p)	Yes	6/18	7/16	0.837 (0.281-2.496)
	No	39/143	43/96	0.510 (0.330-0.788)
t(4;14p)	Yes	10/22	11/20	0.549 (0.232-1.301)
	No	34/137	39/89	0.491 (0.310-0.778)
t(14;16p)	Yes	4/6	N/A	N/A
	No	41/153	50/111	0.501 (0.331-0.757)
Gain(1q)	Yes	26/75	26/52	0.569 (0.330-0.981)
	No	19/84	24/55	0.443 (0.242-0.812)
Number of prior lines of therapy	1	18/80	19/55	0.589 (0.309-1.123)
	>1	30/99	36/68	0.479 (0.294-0.778)
Previous ASCT	Yes	34/116	30/69	0.578 (0.353-0.945)
	No	14/63	25/54	0.428 (0.222-0.825)
Prior PI treatment	Yes	22/81	20/47	0.565 (0.308-1.036)
	No	26/98	35/76	0.493 (0.296-0.819)
Prior IMiD treatment	Yes	22/81	29/62	0.498 (0.286-0.869)
	No	26/98	26/61	0.542 (0.314-0.933)
Refractory to Len	Yes	23/57	25/42	0.598 (0.339-1.055)
	No	5/15	9/17	0.448 (0.149-1.349)
Prior PI + IMiD treatment	Yes	7/23	6/17	0.777 (0.260-2.319)
	No	41/156	49/106	0.494 (0.326-0.749)




FIG. 7